Failing heart—medical aspectsAminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure
Section snippets
Patients
Between January 2002 and January 2004, a total of 550 consecutive patients with heart failure due to left ventricular dysfunction, either as a result of coronary artery disease (CAD) or dilative cardiomyopathy (DCM), presenting to our Interdisciplinary Heart Failure Program were investigated. No exclusion criteria were defined. Patients in good clinical conditions (NYHA Class 1) served as reference group. The demographic data and patient characteristics are shown in Table 1. In all patients,
Baseline characteristics
A total of 550 patients were prospectively investigated. The demographics and baseline characteristics for the study sample according to the underlying heart disease are reported in Table 1. No differences between groups regarding weight, heart rate, ejection fraction, shortening fraction, mean arterial pressure, cardiac index, serum sodium, serum creatinine, and HFSS were observed. Patients with DCM were significantly taller (p < 0.01). Their ventricular diameters left ventricular enddiastolic
Discussion
The poor prognosis associated with advanced heart failure has been demonstrated by Gardner and coworkers.22 They described a 1-year mortality of approximately 15% among patients suffering from advanced heart failure. The recent COPERNICUS Study has provided comparable 1-year mortality rates of 18.5% in the placebo-treated group and 11.4% in the carvedilol-treated group.23, 24 The high mortality rates of end-stage heart failure make it desirable that parameters be found that help identify
References (33)
- et al.
Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction
J Am Coll Cardiol
(2003) - et al.
Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnoea
J Am Coll Cardiol
(2002) - et al.
B-type natriuretic peptide in cardiovascular disease
Lancet
(2003) - et al.
Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease
J Heart Lung Transplant
(2004) - et al.
A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failurea multicenter evaluation
Am Heart J
(2002) - et al.
Recipient selection in cardiac transplantationcontraindications and risk factors for mortality
J Heart Lung Transplant
(2002) - et al.
Screening for and treating left-ventricular abnormalities in diabetes mellitusa new way of reducing cardiac death
Lancet
(2002) - et al.
Plasma brain natriuretic peptide as an indicator for angiotensin-converting enzyme inhibition after myocardial infarction
Lancet
(1993) - et al.
Diagnostic potential of cardiac natriuretic peptides in dialysis patients
Kidney Int
(2001) - et al.
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullinprognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction
J Am Coll Cardiol
(2001)
Prognostic power of neurohormonal parameters in chronic heart failure depends on clinical stage and observation period
J Heart Lung Transplant
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes
N Engl J Med
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure
N Engl J Med
B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure
Circulation
The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure
Clin Chem Lab Med
Natriuretic peptides and acute renal failure
Am J Physiol Renal Physiol
Cited by (65)
Prediction of congestive state in acute and chronic heart failure: The association between NT-proBNP and left atrial strain and its prognostic value
2023, International Journal of CardiologyCitation Excerpt :Interestingly, Carluccio et al. found that reduced PALS (≤12.9%) was associated with advanced New York Heart Association class, higher prevalence of loop diuretic use and greater BNP values; they also demonstrated that lower PALS values were associated with adverse events and HF symptoms, and the outcomes remained significant after adjusting for BNP levels, LAVi, E/e' ratio, and LV GLS [27]. It is well known that NT-proBNP, even if it is limited by low specificity, is a marker of cardiovascular congestion in HF; it also independently predicts morbidity and mortality in chronic HF and has been shown to be a powerful predictor of death and re-hospitalization in HF patients [4–6]. On the other hand, global PALS has been demonstrated to be an index of LV filling pressures and to help in the identification of subjects with diastolic dysfunction [8,14,15].
Advances in congestive heart failure biomarkers
2023, Advances in Clinical ChemistryB-Type Natriuretic Peptide Levels and Mortality in Patients With and Without Heart Failure
2018, Journal of the American College of CardiologySerum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients
2017, Hellenic Journal of CardiologyCitation Excerpt :NT-proBNP concentration was only significant for the prediction of death in the multivariate model. This result may be surprising because NT-proBNP is a recommended marker for heart failure diagnosis, and its prognostic value is well documented.20,21 Our results demonstrated that elevated ST2 concentration in non-ischaemic dilated cardiomyopathy patients with chronic non-decompensated heart failure was associated with worse outcomes.
Prognostic power of NT-proBNP in left ventricular non-compaction cardiomyopathy
2017, International Journal of CardiologyMetabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome
2014, Pharmacology and Therapeutics